Myocet Liposomal (Doxorubicin Hydrochloride)

Doxorubicin Hydrochloride, the active ingredient in Myocet Liposomal, is an anthracycline antibiotic presented as a liposomal injection for intravenous use. The liposomal formulation enhances tumor targeting and reduces cardiac exposure, and it is indicated for the treatment of metastatic breast cancer and ovarian cancer in adult patients.

GNH USA supplies Myocet Liposomal as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring quality‑controlled sourcing from the European market. The company provides full regulatory documentation and cold‑chain logistics where required.

Myocet Liposomal (doxorubicin hydrochloride) is used in oncologic therapy targeting rapidly dividing tumor cells. - Metastatic breast cancer: improves response rates and disease control in patients with advanced disease. - Ovarian cancer: provides therapeutic benefit in recurrent or refractory ovarian carcinoma. - Recurrent ovarian cancer: used as a treatment option when standard chemotherapy has failed.

Myocet Liposomal may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Alopecia: reversible hair loss affecting scalp and body hair. - Fatigue: generalized tiredness that may affect daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell levels causing weakness. - Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects: - Cardiotoxicity: potential for reduced left ventricular function or heart failure. - Severe myelosuppression: profound decrease in all blood cell lines. - Febrile neutropenia: fever associated with low neutrophil count. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Secondary leukemia: rare development of therapy‑related leukemia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

When using Myocet Liposomal, clinicians should observe several safety measures. - Cardiac monitoring: assess baseline left ventricular function and repeat assessments during therapy. - Dose adjustments: modify dosing in patients with hepatic impairment or reduced organ function. - Avoid concurrent cardiotoxic agents: limit exposure to other drugs that may increase cardiac risk. - Monitor blood counts: perform regular CBCs to detect myelosuppression early. - Pregnancy and lactation: use only if potential benefits outweigh risks to mother and fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myocet Liposomal can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent anthracyclines: additive cardiotoxicity may occur. - Live vaccines: immunosuppression increases infection risk. - Chest radiation therapy: combined treatment heightens cardiac toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals: may raise plasma levels of doxorubicin. - Strong CYP450 inhibitors: potential alteration of drug metabolism. - St. John’s wort: herbal induction may reduce therapeutic efficacy.